Molecular diagnostic company Myriad Genetics has partnered with The University of Texas MD Anderson Cancer Center to conduct research focusing on treatment selection and response for metastatic renal cell carcinoma (RCC).
The collaboration will utilize Myriad's minimal residual disease (MRD) testing platform, designed to detect circulating tumor DNA (ctDNA) in individuals with metastatic RCC and other cancers. The MRD testing system utilizes whole-genome sequencing, enabling the identification and tracking of thousands of variants present in the tumor, resulting in a tumor-informed, high-definition assay.
The research project aims to explore the potential of Myriad's MRD testing platform as a non-invasive tool for guiding treatment selection, monitoring disease progression, and assessing radiotherapy treatment response in individuals with metastatic RCC.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.